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Abstract
Staphylococcus aureus virulence has been associated with the production of phenol soluble modulins (PSM). PSM are known
to activate, attract and lyse neutrophils. However, the functional characterizations were generally performed in the absence
of human serum. Here, we demonstrate that human serum can inhibit all the previously-described activities of PSM. We
observed that serum can fully block both the cell lysis and FPR2 activation of neutrophils. We show a direct interaction
between PSM and serum lipoproteins in human serum and whole blood. Subsequent analysis using purified high, low, and
very low density lipoproteins (HDL, LDL, and VLDL) revealed that they indeed neutralize PSM. The lipoprotein HDL showed
highest binding and antagonizing capacity for PSM. Furthermore, we show potential intracellular production of PSM by S.
aureus upon phagocytosis by neutrophils, which opens a new area for exploration of the intracellular lytic capacity of PSM.
Collectively, our data show that in a serum environment the function of PSM as important extracellular toxins should be
reconsidered.
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Introduction
Staphylococcus aureus frequently colonizes human anterior nares
and can cause many infectious diseases, ranging from mild
superficial skin and wound infections to life-threatening dissem-
inated infections [1]. The number of infections by this bacterium is
increasing, especially infections caused by methicillin-resistant S.
aureus (MRSA) strains. However, infections are still limited to a
small percentage of colonized individuals. This suggests that the
human innate immune system together with physical and humoral
barriers can very effectively control invasive infections, even those
caused by the invasive community-associated (CA) MRSA.
Therefore, we hypothesize that virulence factors produced by S.
aureus are likely generally counteracted by the innate immune
system, and that a balance between the two determines the
outcome of an infection.
In order to survive within the host, S. aureus can make use of a
variety of virulence factors [2], including a repertoire of toxins [3].
The toxins induce host cell lysis and include superantigens,
leukocidins and phenol soluble modulins (PSM). In contrast to
most other toxins, PSM are small core genome-encoded peptide
toxins, except for PSM-mec, which is located on the methicillin
resistance-encoding MGE staphylococcal cassette chromosome
SCCmec [4]. The production of PSM is controlled by the quorum-
sensing accessory gene regulator (agr) [5], and the gene expression
levels correlate with strain virulence. Especially CA-MRSA strains
are associated with high productions of PSM, which is thought to
account for the enhanced virulence, easier spreading and severity
of infection of CA-MRSA strains compared to hospital-acquired
MRSA strains (HA-MRSA) [6,7]. Thus far, all described PSM
have a common amphipathic alpha helical region, which is
thought to enable their cell lytic ability most likely by disrupting
the cell membrane [7]. Despite having a similar structure, PSM
are categorized in two groups, depending on their size. The
smaller a-type PSM (PSMa1, PSMa2, PSMa3, PSMa4, and d-
toxin), with a length of 20–30 amino acids, are regarded as the
most toxic PSM [7], whereas the larger b-type PSM (PSMb1 and
PSMb2) of approximately 44 amino acids seem to have additional
functions. For instance, b-type PSM of S. epidermidis are described
to play a role in biofilm dispersal [8].
Next to lysing neutrophils, PSM are described to activate and
attract leukocytes. Neutrophils are the first leukocytes recruited to
the site of infection and are crucial in controlling staphylococcal
infections. They are attracted by both host factors and conserved
microbial molecules also known as pathogen-associated molecular
patterns (PAMPs). Although many PAMPs are recognized by Toll-
like receptors (TLRs) [9], PSM are potent staphylococci-specific
PAMPs which act mainly on the human formylated peptide
receptor 2 (FPR2) [10]. FPR2 is expressed on neutrophils,
monocytes, macrophages, immature dendritic cells, and microglial
cells, and its activation induces many neutrophil effector functions,
including chemotaxis, exocytosis and superoxide generation [11].
While micromolar concentrations of PSM are needed for
neutrophil lysis, nanomolar concentrations are enough for
FPR2-mediated neutrophil stimulation. Although neutrophils
sense PSM at nanomolar concentrations, S. aureus can subvert
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protein (FLIPr) [12] and its homologue FLIPr-like [13].
S. aureus typically resides in mucosal en epithelial surfaces and
can invade beyond these physical barriers causing invasive
infections. The switch from a colonizing phenotype to a virulent
phenotype is regulated by agr [14]. This regulatory switch relies on
the secretion of autoinducing peptide (AIP) sensed by the cell
population and triggers the expression of virulence determinants
such as proteases, haemolysins and toxins. To fight the infection,
the human innate immune system has several effector mecha-
nisms, both humoral and cellular, to clear the invading bacterium.
Recently, Peterson et al [15] described a novel neutralizing
mechanism; incorporating ApoB1 in VLDL and LDL lipoproteins
in serum can sequester AIP and thereby disable staphylococcal
quorum sensing. Mice lacking plasma ApoB1 are more susceptible
to invasive staphylococcal infections, implicating that ApoB1 is an
essential innate defense effector against S. aureus [15]. The current
study shows that serum also provides a barrier against the pro-
inflammatory and cytolytic activities of PSM, the highest agr-
upregulated virulence factor of S. aureus. Our main finding is that
PSM-induced activation and lysis of neutrophils are greatly
inhibited by human serum. Lipoprotein particles were identified
as the PSM-binding and -inhibiting components within serum,
suggesting that they function as scavengers of PSM, thereby
preventing host damage. We show that S. aureus potentially can
produce PSM inside neutrophils after phagocytosis. This opens a
new area of exploration of the intracellular toxic capacity of PSM.
Results
Activation and lysis of neutrophils by staphylococcal
culture supernatants is inhibited by human serum
Inflammatory PSM activities are generally studied in normal
culture medium without the addition of serum [4,7,10,16]. We
hypothesized that constituents of human serum could inhibit S.
aureus virulence by interfering with PSM activity at sites of
infection. First we studied the influence of serum on the FPR2-
stimulatory capacity of PSM produced by S. aureus. Therefore, we
used an FPR2-transfected HL-60 cell line (HL-60/FPR2), and
examined the activating capacity of culture supernatants of wild
type (WT) MW2 strain and an isogenic agr knockout (MW2 agr
KO) strain, which is described not to produce PSM [10]
(Figure 1A). Without serum, the supernatant of WT MW2
activated HL-60/FPR2 cells very potently, in contrast to the
supernatant of the MW2 agr KO strain. Addition of 1% normal
human serum reduced the activity of the supernatant of WT MW2
to the level induced by the MW2 agr KO supernatant. The FPR2-
activation by the MW2 agr KO supernatant was not affected by
the addition of human serum, suggesting that human serum
specifically inhibits the PSM-induced FPR2-activation. The
inhibition of PSM-induced FPR2 activation by human serum
was not species specific, as the addition of mouse, rabbit or bovine
serum also inhibited the activation of HL-60/FPR2 cells by the
WT MW2 supernatant (data not shown).
Next to the FPR2-activating capacity of S. aureus culture
supernatants, the MW2 supernatant has also been described to
Figure 1. Human serum inhibits the activity of PSM in culture
supernatants. (A) Dose-dependent calcium mobilization of HL-60/
FPR2 cells by culture supernatants of S. aureus strains MW2 and MW2
agr KO, with or without preincubation with 1% heat-inactivated human
serum. (B) Dose-dependent neutrophil lysis by S. aureus culture
supernatants with or without preincubation with 5% heat-inactivated
human serum. Neutrophil lysis was measured through LDH release.
Data represent means 6 SEM of three independent experiments.
doi:10.1371/journal.ppat.1002606.g001
Author Summary
Infections with methicillin-resistant Staphylococcus aureus
(MRSA) are difficult to treat because of resistance against
standard antibiotics. In contrast to the traditional health-
care-associated (HA-) MRSA strains, community-associated
(CA-) MRSA strains cause severe infections in otherwise
healthy individuals. CA-MRSA strains display enhanced
virulence, spreading more rapidly and causing more severe
illness than HA-MRSA strains. Enhanced virulence of CA-
MRSA is thought to be associated with the production of
several toxins, such as Phenol Soluble Modulins (PSM). PSM
have been described to activate, attract and lyse
neutrophils. Thus far, previous studies characterizing the
functions of PSM were performed in the absence of body
fluids. In the current study, we show that human serum
strongly inhibits many functions attributed to PSM. We
demonstrate that serum lipoprotein particles are respon-
sible for the binding and inhibition of PSM, even when
PSM are produced by growing S. aureus in whole blood.
Finally, we show production of PSM by S. aureus within
neutrophils, suggesting that PSM may play a role
intracellularly in a serum-free environment. These findings
significantly contribute to our understanding of the
function of PSM and strongly suggest that PSM, instead
of performing as extracellular toxins, most likely act as
intracellular toxins.
Inactivation of PSM by Serum Lipoproteins
PLoS Pathogens | www.plospathogens.org 2 March 2012 | Volume 8 | Issue 3 | e1002606very potently lyse isolated human neutrophils [7]. Therefore, we
investigated the effect of serum on the culture supernatants of the
same S. aureus strains in their capacity to lyse neutrophils. Indeed,
the culture supernatant of WT MW2 very potently lysed human
neutrophils, as measured by the release of LDH, in contrast to the
supernatant of the MW2 agr KO (Figure 1B). Also in this assay,
5% human serum completely abrogated the lysis of human
neutrophils induced by the culture supernatant of WT MW2,
while leaving the effect of the MW2 agr KO supernatant
uninfluenced. Agr not only regulates the production of PSM, but
also controls the expression of other toxins, for instance the alpha
toxin gene (hla). Based on the known functions of PSM, especially
their FPR2 activating capacity, we hypothesize that PSM are the
main effectors causing the differences in cell activation and lysis
between the WT MW2 and the MW2 agr KO supernatants.
Therefore, we think that PSM are specifically inhibited by human
serum. As described by others [7,10], we also observed that the
percentage S. aureus MW2 supernatant needed for neutrophil lysis
is 1000 times higher than that needed for FPR2 activation.
Not only S. aureus strain MW2, but also strains USA300 and
Newman are known to produce high levels of PSM. In contrast,
strains N315 and COL have been described to produce low levels
of PSM [7,10]. When we examined the activity of the supernats of
these S. aureus strains, our results correlated with the described
production of PSM. FPR2-induced cell activation and neutrophil
lysis were only induced by the supernatants of the high PSM-
producing S. aureus strains. Importantly, these activities were also
potently inhibited by human serum (Figure S1A and S1B). Our
findings thus suggest that human serum inhibits the FPR2-
activation and neutrophil lysis induced by S. aureus produced PSM.
Human serum inhibits the PSM-induced activation of
neutrophils
To demonstrate that human serum indeed targets PSM present
in the supernatant of S. aureus, we also tested its activity on
synthetic PSM. All S. aureus core genome-encoded PSM were
tested, with the exception of PSMmec, for FPR2 stimulatory
activity in the presence and absence of human serum. Pre-
incubation of pure synthetic PSM with 0.1% human serum
significantly inhibited the ability of all PSM to elicit calcium
mobilization in neutrophils, whereas control stimuli, fMLP, IL-8
and C5a, were not inhibited (Figure 2A). The supernatant of S.
aureus strain MRSA252 containing PSMmec was also inhibited by
human serum. Although not examined for synthetic PSMmec,
Figure 2. Human serum inhibits PSM-mediated neutrophil activation. (A) Calcium mobilization of human neutrophils. Neutrophils were
stimulated with 10
26 M PSMa1, 10
27 M PSMa2, 10
27 M PSMa3, 10
26 M PSMa4, 3610
26 M d-toxin, 10
25 M PSMb1, 10
25 M PSMb2, 10
29 M fMLP,
10
210 M C5a and 10
210 M IL-8, all preincubated with or without 0.1% heat-inactivated human serum, before calcium mobilization was measured by
flow cytometry. *, p,0.001; N.S., not significant. (B) Time-dependent inhibition of PSMa3-mediated calcium mobilization of HL60/FPR2 cells. PSMa3,
100 nM or 500 nM, was preincubated with 0.1% human serum and calcium mobilization was measured at different time-points by flow cytometry. (C)
Dose-response curves for calcium mobilization in HL-60/FPR2 cells induced by PSMa3 or serum-treated PSMa3. Data represent means 6 SEM of at
least three independent experiments.
doi:10.1371/journal.ppat.1002606.g002
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PSMmec than to other PSM. To investigate the kinetics of serum-
induced PSM-inactivation, the incubation time of PSM with
serum was varied from 0 to 1800 sec, before testing in a calcium
mobilization assay using HL-60/FPR2 cells. 100 nM PSMa3 was
inactivated by 0.1% serum within seconds, whereas inactivation of
a 5 times higher PSM concentration was clearly delayed
(Figure 2B). Higher concentrations of PSM of up to 1 mM could
be fully inhibited by 15 minutes pre-incubation with 1% serum
(Figure 2C). These results indicate a time- and dose-dependent
inhibition of PSM-induced FPR2-activation by human serum.
Human serum inhibits the S. aureus PSM-induced
neutrophil lysis
In order to investigate the ability of human serum to inhibit
PSM-induced neutrophil lysis, we screened the synthetic PSM
peptides preincubated with serum for neutrophil lysis. For this, we
used a concentration range of 400 nM to 100 mM for each PSM.
These concentrations are biologically relevant, as Wang et al [7]
have described that the CA-MRSA MW2 and USA300 strains
produce d-toxin up to 30 mM in an overnight culture. Other a-
type PSM are typically produced at somewhat lower concentra-
tions, ranging from 5 mMt o1 5 mM. The cytolytic activity of
PSMa1, PSMa2, PSMa3, and d-toxin towards neutrophils was
completely abrogated in the presence of serum (Figure 3). In
addition, the lysis of peripheral blood mononuclear cells by
synthetic PSMa3 was inhibited by human serum (Figure S2A). To
investigate whether other staphylococcal toxins may also be
inhibited by human serum, we tested the effect of serum on PVL-
mediated lysis. The lysis of neutrophils induced by PVL toxin was
not affected by human serum (Figure S2B), implicating that serum
does not generally inhibit all toxin-mediated cell lysis. As shown
previously [7], a-type PSM are very potent in cytolysis; however,
in our hands neutrophil lysis by b-type PSM under physiologically-
relevant concentrations was not observed. Collectively, we
demonstrated that serum inhibits the FPR2-activating and
neutrophil lysing capacity of all S. aureus PSM.
PSM interact with serum lipoproteins
To capture the serum components able to inactivate PSM, we
coated CNBr-Sepharose beads with synthetic S. aureus PSMa1o r
PSMa3 and incubated the generated beads with 20% heat-
inactivated serum. Following extensive washing, the specifically-
bound proteins were eluted, analyzed by non-reducing SDS-
PAGE and visualized by Instant Blue staining (Figure 4A). Both
PSMa1 and PSMa3 bound to a protein of approximately 25 kDa,
which was identified by mass spectrometry as ApoA1. Interest-
ingly, when we performed the same experiment and additionally
Figure 3. Inhibition of PSM-mediated neutrophil lysis. Dose-dependent neutrophil lysis by synthetic PSMa1, PSMa2, PSMa3, and d-toxin
(400 nM to 100 mM), preincubated with or without 1% or 10% human serum. Neutrophil lysis was measured through LDH release. Data represent
means 6 SEM of three independent experiments.
doi:10.1371/journal.ppat.1002606.g003
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detergent, ApoA1 was not longer detected. We were unable to
detect a direct interaction of immobilized PSM with recombinant
ApoA1 using ELISA or Surface Plasmon Resonance (data not
shown). ApoA1 is however the major protein constituent of high
density lipoprotein (HDL), which could possibly bind PSM. Serum
lipoproteins are complex particles with a neutral core containing
triglycerides and cholesterol and covered by an amphipathic
monolayer of phospholipids and unesterified cholesterol. The Apo-
protein components bind to the surface of the particles and are
either restricted to particular lipoproteins or freely exchangeable
across lipoprotein categories. Therefore, the inability of PSM to
bind to ApoA1 in the presence of a detergent most likely indicates
that PSM bind to the lipid content of the HDL particle rather than
a specific interaction with ApoA1. To test this hypothesis, we
performed serum size exclusion assays with FITC-labeled PSMa3
(PSMa3-FITC) to find the PSM-binding components in serum.
The FITC-labeling did not affect the function of the PSMa3
molecule, as PSMa3-FITC was as potent as unlabeled PSMa3i n
the FPR2-activation of neutrophils (Figure S3). At first, the
retention volume of PSMa3-FITC was determined; PSMa3-FITC
behaved as an aggregate of peptides in a physiological buffer,
resulting in a broad peak of approximately 50 kDa (Figure 4B). In
contrast, when a similar size exclusion run was performed in the
presence of a detergent, a peak of monomeric PSMa3-FITC of
approximately 2,5 kDa was observed. This is in line with the first-
described discovery of PSM, where similar poly-peptide complexes
were observed when PSM were extracted from S. epidermidis
culture supernatant [17].
Multimeric aggregations have also been reported for S. aureus d-
toxin with molecular weights of 5–200 kDa, with the lower
molecular weights observed at extreme pH or in organic solvents,
and the larger molecular weights observed in water [18,19].
Interestingly, when PSMa3-FITC was incubated with human
serum prior to the size exclusion assay, the 50 kDa peak shifted
towards two peaks, one of 150 kDa and one larger than 500 kDa,
Figure 4. PSM associate with serum lipoproteins. (A) Serum pull down assay with PSMa1 and PSMa3 coupled to CNBr beads. Beads were
extensively washed with PBS or PBS with tween (PBST). Serum proteins bound and eluted from the beads were visualized by SDS-page followed by
instant blue staining. Protein bands specifically appearing in the PSMa1 and PSMa3 lane were identified by MALDI-TOF mass spectrometry as ApoA1.
(B) Gel filtration association assay. Comparison of absorption (OD492 nm) profiles of 100 mg/ml PSMa3-FITC pre-incubated with PBS, 10% human
serum, 1 mg/ml HDL, 1 mg/ml LDL or 1 mg/mL VLDL for 30 min, before separation on a gel filtration column. For monomerization of PSMa3-FITC,
the gel filtration column was equilibrated with PBS containing 0.1% sodium deoxycholate (DOC). Representative figures of two independent
experiments.
doi:10.1371/journal.ppat.1002606.g004
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and low density (LDL) or very low density (VLDL) lipoproteins,
known to run at higher than 500 kDa. To demonstrate that indeed
PSMa3-FITC associated with lipoproteins in serum, we purified
HDL and LDL from serum and repeated the size exclusion
experiment using PSMa3-FITC preincubated with purified HDL
or LDL. When PSMa3-FITC was preincubated with HDL,
detection of the FITC signal shifted from a molecular weight of
50 kDa towards 150 kDa, whereas the signal of PSMa3-FITC
preincubated with LDL, which, as VLDL, represents high
molecular weight particles, shifted to the void volume of the gel
filtration column. Importantly, the fluorescent 150 and .500 kDa
peaks of the size exclusion chromatograms of PSMa3-FITC and
serum correspond and are overlapping with the peaks of the size
exclusion chromatograms of PSMa3-FITC with HDL and
PSMa3-FITC with LDL or VLDL. As the interactions of
PSMa3-FITC with HDL, LDL or VLDL do not shift the
retention times of these lipoproteins on the gel filtration column, it
appears that only monomeric PSMa3-FITC molecules interact
with the lipoprotein particles (Figure S4). In conclusion, several
serum lipoproteins can associate with PSM.
Lipoproteins antagonize PSM
We further investigated whether serum lipoproteins, by binding
PSM, are responsible for antagonizing the functions of PSM.
Therefore, we depleted normal human serum for lipoproteins by
density ultracentrifugation. Compared to untreated serum,
lipoprotein-depleted serum lost the ability to inhibit the PSM
induced lysis of neutrophils (Figure 5A), indicating that lipopro-
teins are indeed the serum components that inhibit PSM. Next, we
tested the effect of purified HDL and LDL on PSM-function.
Normal HDL or LDL protein levels in serum are between 1 and
1.3 mg/ml. Purified HDL and LDL at physiologically relevant
concentrations, representing serum levels of 1 and 10%, inhibited
the PSM-mediated lysis of neutrophils (Figure 5B). In addition,
HDL and LDL inhibited the calcium mobilization induced by
synthetic PSM (Figure 5C). Addition of recombinant ApoA1 or
ApoB1 did not inhibit the PSM induced activation (Figure S5A) or
lysis (Figure S5B) of neutrophils. To determine the serum
lipoprotein with the highest neutralizing capacity, we separated
human serum by size exclusion chromatography. Subsequently,
the separate fractions were tested for inhibition of a high or a low
lethal dose of PSMa3 (Figure 6). At the high lethal dose (50 mM)
only the fractions containing HDL inhibited neutrophil lysis,
whereas at a lower still lethal dose (10 mM) also LDL/VLDL could
inhibit the lysis of neutrophils, indicating that HDL is the most
potent inhibitor within human serum. Next, human serum was
spiked with PSMa2, and HDL, LDL, VLDL and lipid-free serum
were isolated by density ultracentrifugation and analyzed by
HPLC (Figure 6C). Approximately 80% of the spiked PSMa2 was
found in the HDL-containing fractions, whereas approximately
15% and 5% of PSM was recovered in LDL- and VLDL-
containing fractions, respectively. We did not detect PSM in the
lipid-free serum. Finally, we investigated whether PSM could also
be recovered in serum constituents when S. aureus was cultured in
blood. Therefore, we cultured S. aureus MW2 overnight in freshly
Figure 5. Serum lipoproteins inhibit PSM-mediated neutrophil lysis and activation. (A) Dose-dependent neutrophil lysis by synthetic
PSMa3 preincubated with 1% and 10% human serum or human lipid-free (LF) serum or preincubated with (B) 5 and 50 mg/ml HDL or 10 and 100 mg/
ml LDL (concentrations are based on protein content). PBS was used as buffer control. Neutrophil lysis was measured via LDH release. (C) Calcium
mobilization of human neutrophils. Neutrophils were stimulated with 10
26 M PSMa1, 10
27 M PSMa2, 10
27 M PSMa3, 10
26 M PSMa4, 3610
26 M d-
toxin, 10
25 M PSMb1, 10
25 M PSMb2, 10
29 M fMLP, 10
210 M C5a and 10
210 M IL-8, all preincubated with or without 5 mg/ml HDL or LDL, before
calcium mobilization was measured by flow cytometry. *, p,0.001; N.S., not significant.
doi:10.1371/journal.ppat.1002606.g005
Inactivation of PSM by Serum Lipoproteins
PLoS Pathogens | www.plospathogens.org 6 March 2012 | Volume 8 | Issue 3 | e1002606Inactivation of PSM by Serum Lipoproteins
PLoS Pathogens | www.plospathogens.org 7 March 2012 | Volume 8 | Issue 3 | e1002606drawn lepirudin-anticoagulated blood, isolated the HDL fraction
from the clarified blood the following day and analyzed it by
HPLC/LC MS. Figure 6D shows the presence of PSMa1,
PSMa2, PSMa3, PSMa4 and d-toxin in the purified HDL
fraction, indicating that PSM produced by viable S. aureus could be
neutralized by lipoproteins in a blood environment.
PSMa is produced by S. aureus upon phagocytosis by
neutrophils
Thus far, our data strongly suggest that the functional properties
of PSM produced by S. aureus in serum as well as in whole blood
are inhibited by lipoproteins. These results conflict with literature
describing PSM as key virulence determinants for CA-MRSA,
with regard to their cell lytic properties [7]. Therefore, we
hypothesized that PSM rather act as toxins in an environment
devoid of lipoproteins, such as the neutrophil phagosome. To test
whether PSM could act intracellular and are produced by S. aureus
after uptake by human neutrophils, we generated a construct in
which the promoter of the PSMa operon drives GFP expression.
This PSMa promoter-GFP construct was transformed into S.
aureus MW2, the bacterium was cultured over time, and the
activation of the PSMa promoter was monitored with a
fluorescent plate reader. As expected for an agr-controlled
expression, the GFP expression was detected during the late
logarithmic growth phase. Under these conditions, we did not
observe expression of GFP when we introduced the construct in
the MW2 agr KO strain (data not shown). Next, we examined GFP
expression upon phagocytosis of MW2 bacteria containing the
PSMa promoter-GFP construct by neutrophils. Therefore, the
bacteria were first cultured to very early logarithmic phase to
prevent initial activation of the PSMa promoter. Then, they were
opsonized with human serum, presented to neutrophils adherent
to a flow cell, and bacterial fluorescence upon phagocytosis by
neutrophils was assayed over time with a fluorescent microscope.
Fluorescence within neutrophils was observed 45 min to 2 hours
after phagocytosis (Figure 7+Video S1), indicating activation of the
PSMa promoter and thus potential production of PSMa inside
neutrophils. We did not observe fluorescence for bacteria found
outside neutrophils, except when they formed dense micro-
colonies (data not shown). These data indicate potential PSMa
expression inside neutrophils after phagocytosis of S. aureus.
Discussion
Serum transports the humoral components of the innate
immune system throughout the human body. Apart from the
Figure 6. Identifying the most potent inhibitor of PSM in serum. Functional screening of serum fractions, isolated by gel filtration, for the
inhibition of neutrophil lysis. Serum fractions were incubated with (A) 50 mM or (B) 10 mM of PSMa3 before addition to neutrophils and neutrophil
lysis was measured via LDH release. Data represent means 6 SEM of three independent experiments. (C) PSM concentration measured in isolated
lipoprotein fractions after spiking human serum with 0.5 mg/ml PSMa2. PSM concentration was measured by reverse phase-HPLC and represents the
mean of the area under the curve of PSMa2 of 3 independent experiments. (D) Measurement of the concentration PSM by HPLC in isolated HDL
fraction from an overnight whole blood culture of the S. aureus MW2 strain (black line) or control (no bacteria; gray line). HDL fractions were
subjected to HPLC and absorbance at 214 nm was obtained. Respective PSM were identified by LC/MS, d-toxin and PSMa2 were contained in the
same peak in this assay condition.
doi:10.1371/journal.ppat.1002606.g006
Figure 7. Rapid upregulation of PSMa expression after phagocytosis. S. aureus MW2 containing the PSMa promoter-GFP construct was
incubated with neutrophils, and fluorescence as a measure for PSMa expression was monitored over time (0–3 hours). Arrows indicate neutrophils
which have phagocytozed S. aureus. (*) Indicate growing reporter bacteria outside of the cells. Bars: 50 mm.
doi:10.1371/journal.ppat.1002606.g007
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system has been found to play a role in innate immunity as well.
ApoB1, the major protein constituent of VLDL and LDL, can
sequester AIP and thereby prevent quorum sensing of S. aureus
[15]. We show in this study that serum lipoproteins dampen
inflammatory over-stimulation and inhibit the cytolytic activities of
the agr-controlled PSM. PSM are sequestered by serum lipoprotein
particles and thereby lose their functional properties, which may
allow their clearance from the system, analogous to LPS
sequestration by HDL [20]. This has great implications for our
understanding of PSM function during infection. All classes of
plasma lipoproteins are normally present in interstitial tissue fluids
at approximately 6% of the plasma concentration for VLDL to
20% for HDL [21]. This interstitial lipoprotein concentration even
increases in case of inflammation. Although PSM can lyse
neutrophils and S. aureus can produce PSM in very large quantities
[6,7], the majority of these PSM will most likely rapidly be
neutralized by serum lipoproteins, making it unlikely that the high
concentrations required to cause neutrophil lysis can be reached.
Therefore, we propose that the role of PSM as important secreted
extracellular toxins should be reconsidered.
We do not rule out a possible role for the membrane-lytic effects
of PSM within neutrophils after phagocytosis of S. aureus.
Intracellular lysis could account for the fact that experimental
mouse studies with PSM knockout S. aureus strains show reduced
virulence [4,7]. It has recently been described that the concentra-
tion of AIP, responsible for gene transcription upon quorum
sensing, can reach the critical concentration within cells, allowing
the agr system to function within the neutrophil [22,23]. In line
with these studies, we show that the promoter for the PSMa
operon is activated after phagocytosis of S. aureus by neutrophils.
This strongly suggests that PSMa cytolytic peptides are produced
within the neutrophil phagosome and may have a function there.
Since the neutrophil phagosome is devoid of lipoprotein particles,
PSM may act intraphagosomally and allow S. aureus to escape from
the phagosome and thereby avoiding killing. Similarly, staphylo-
coccal alpha toxin (Hla), has been demonstrated to allow
endosomal escape after phagocytosis [24,25]. However, further
research is needed to test whether PSM have a similar mechanism
of action. Next to the neutrophil phagosome, other niches within
the human body lacking serum lipoproteins may allow for
extracellular PSM functions.
PSM are thought to lyse cells by disrupting the cell membrane.
S. aureus delta toxin is proposed to form a cation-selective
membrane pore with a central hydrophilic channel by the
multimerization of 6 monomers and an outer hydrophobic
interaction with membrane lipid [18,26]. The intrinsic structural
properties of the amphipathic alpha helix of PSM likely mediate a
similar multimerization in response to a lipid bilayer. This implies
that PSM randomly insert into lipid membranes without specific
targeting of host cells. In line with this, PSMc and PSMd from S.
epidermidis have been shown to perforate synthetic POPC/POPG
((1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine)/(1-palmitoyl-
2-oleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)]) lipid vesicles [27].
PSM thus seem to target lipid layers without the presence of
membrane proteins, suggesting that there is no species specificity.
This is in contrast to other staphylococcal cytolytic toxins, such as
PVL, which show strong human specificity [28]. Staphylococcal
two-component toxins are proposed to induce receptor-mediated
lysis, which explains why they are not inhibited by human serum
lipoproteins. PSM seem to have high affinity for lipids. Therefore,
it is not surprising that their biological actions are inhibited by the
major humoral lipid transportation system, the lipoprotein
particles. The two most abundant serum lipoprotein particles are
HDL and LDL. Although the normal serum concentration of
LDL (ApoB1 1.6 mg/ml) is higher than the HDL (ApoA1
1.2 mg/ml), the combined surface of the HDL particles exceeds
3 times the surface of LDL particles. The surface size difference
therefore most likely accounts for the higher inhibitory potential of
HDL compared to LDL.
As we clearly show that PSM not only interact with HDL, but
also with LDL and VLDL, we argue that the Apo proteins within
the lipoprotein particles do not play a specific role in binding the
PSM. Although we tried, we could indeed not detect a direct
interaction between purified APO-proteins and synthetic PSM. In
addition, PSM are unable to bind to lipoprotein particles in the
presence of a detergent, and PSM can interact with synthetic lipid
vesicles [27]. Therefore, we expect that PSM bind to the lipid
contents of the lipoprotein particles without the need for a specific
interaction with Apo proteins within the complexes.
PSM have the capacity of attracting neutrophils in the
nanomolar range, exceeding their lytic capacity over a 1000 fold.
There is increasing evidence that S. aureus can survive inside
neutrophils [29] and that intracellular survival contributes to
pathogenesis [30]. Neutrophil attraction to the site of infection
may thus possibly be advantageous for the bacterium. On the one
hand, it has been demonstrated that neutrophils are necessary to
control the infection; to subvert neutrophil attraction through
FPR2 S. aureus can also secrete two FPR2 antagonists, FLIPr or
FLIPr-like [12,13] and prevent excessive PSM-induced neutrophil
migration. The higher PSM production of CA-MRSA strains, as
compared to HA-MRSA strains, might however tilt the balance in
favour of neutrophil migrating towards the infection side. Then, a
higher PSM production inside the neutrophils upon S. aureus
phagocytosis may rescue CA-MRSA from phagosomal killing,
contributing to its enhanced virulence.
Serum lipoproteins have a well-known function in dampening
immune responses. As for PSM, lipopolysaccharide (LPS) and
lipoteichoic acid can be inactivated by human serum lipoproteins
[31–33]. Also comparable to PSM, LPS forms large aggregates in
aqueous conditions. Moreover, both PSM and LPS are taken up
by HDL as monomeric molecules, resulting in their inactivation.
The process of LPS- and PSM-inactivation by HDL displays
different kinetics, since it takes hours for HDL to take up LPS [34],
whereas we show uptake of PSM by HDL within seconds. For
LPS, the serum components LPS-binding protein (LBP) and
soluble CD14 (sCD14) catalyze the process of LPS transfer. Both
LBP and sCD14 bind to the toxic Lipid A moiety of LPS and
facilitate the transfer of monomeric LPS to HDL or to cellular
expressed CD14, resulting in inactivation of LPS and activation of
the LPS receptor TLR4, respectively. Thus far, there is no
evidence that a similar serum transfer system exists for the transfer
of PSM to lipoproteins or the recognition of PSM by FPR2. Our
data show that isolated HDL, without the addition of other serum
components, is sufficient for PSM transfer to HDL. Additionally,
we show no enhancement of the FPR2 activating capacity of PSM
in the presence of lipoprotein deficient serum, as compared to
buffer only. These results strongly suggest that no serum
component is needed for the PSM inactivation by lipoproteins
or the PSM recognition by FPR2.
High production of PSM by CA-MRSA strains is proposed as
the causative factor for the enhanced virulence of CA-MRSA
strains, as compared to HA-MRSA strains [6,7]. Our current
study shows strong interaction and neutralization of PSM by
serum lipoproteins, even when PSM are produced by growing S.
aureus in whole blood. These results strongly suggest that the
contribution of PSM to the enhanced virulence of CA-MRSA
strains is not due to PSM acting as extracellular toxins. PSM can
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body. Low non-toxic concentrations of PSM might attract
neutrophils to the site of infection enabling uptake of S. aureus.
Once inside the cell, production of PSM might help S. aureus in its
escape from the phagosome, aiding in its survival and virulence.
The antimicrobial activity of PSM against other bacteria might
also create a niche for staphylococcal colonization outside the
human body. Future studies are needed to shed more light on the
exact functions of PSM and their contributions to CA-MRSA
virulence.
Materials and Methods
Ethics statement
Informed written consent was obtained from all donors and was
provided in accordance with the Declaration of Helsinki. Approval
was obtained from the medical ethics committee of the University
Medical Center Utrecht (Utrecht, The Netherlands).
Reagents
PSM peptides were synthesized with the recently published
sequences [7] by Genscript at 95% purity. PSMa1 (MGIIAGIIK-
VIKSLIEQFTGK), PSMa2 (MGIIAGIIKFIKGLIEKFTGK),
PSMa3 (MEFVAKLFKFFKDLLGKFLGNN), PSMa4 (MAIVG-
TIIKIIKAIIDIFAK), PSMb1 (MEGLFNAIKDTVTAAINND-
GAKLGTSIVSIVENGVGLLGKLFGF), PSMb2 (MTGLAEA-
IANTVQAAQQHDSVKLGTSIVDIANGVGLLGKLFGF), d-
toxin (MAQDIISTISDLVKWIIDTVNKFTKK) were all synthe-
sized with an N-terminal formyl methionine residue. Peptide
stocks were prepared at 2 mM dissolved in H2O except PSMa4,
which was dissolved in 50% (v/v) MeOH/H20. Peptide grade
TFA, and HPLC grade MeOH were purchased from Biosolve.
fMLP, FITC-isomers, and C5a were obtained from Sigma
Aldrich. IL-8 was purchased from PeproTech. HDL, LDL, VLDL
and ApoB1 were purchased from (Millipore). Apo-A1 was
purchased from (Calbiochem). PVL components LukS and LukF
were kindly provided by Gerard Lina, Centre National de
Re ´fe ´rence des Staphylocoques, Lyon, France.
Bacterial strains
In this study the Staphylococcus aureus strains COL, N315,
MRSA252, Newman, MW2 and USA300 were used. MW2 agr
knockout [35] was a kind gift of Alexander Horswill, the
University Of Iowa, Iowa, USA. S. aureus strains were cultured
overnight in Mu ¨ller-Hinton broth (MHB) with shaking at 37uC.
Alternatively, MW2 was grown in MHB until an OD660 of 1.0.
Bacteria were washed with PBS and 10
6 CFU/ml was added to
freshly drawn whole human blood anticoagulated with 50 mg/ml
lepirudin (Refludan, Schering). Bacteria were cultured overnight
in whole blood with shaking at 37uC. Bacterial culture
supernatants or whole blood culture plasma were clarified by
centrifugation, filtered through 0.22 mm pore size filter and stored
at 220uC in aliquots until use.
Human neutrophils
Human neutrophils were isolated by means of the Ficoll-
Histopaque gradient method. Venous heparinized blood was
diluted with an equal volume of PBS, and subsequently layered on
a gradient of Ficoll (Amersham Biosciences) and Histopaque
(Sigma Aldrich). After centrifugation for 20 min at 400 g and
21uC, polymorphonuclear cells (neutrophils) were collected from
Ficoll and Histopaque interfaces. Cells were washed with cold
RPMI-1640 containing 25 mM HEPES, L-glutamine (Biowhit-
taker), and 0,05% human serum albumin (HSA; Sanquin) (RPMI-
HSA). Erythrocytes were lysed by applying a hypotonic shock to
the neutrophil pellet with distilled H2O for 30 sec, followed by
106 concentrated PBS to restore the isotonicity. The cells were
washed and resuspended in RPMI-HSA. HL-60 cells stable
transfected with the FPR2 (HL-60/FPR2), were kindly provided
by F. Boulay (Laboratoire Biochimie et Biophysique des Systemes
Integres, Grenoble, France). Cells were cultured in RPMI-1640
supplemented with 10% fetal bovine serum (FCS), 2 mm, 100
units/ml penicillin, 100 mg/ml streptomycin, and 600 mg/ml
G418.
Serum and lipoprotein preparations
Human pooled serum was obtained from at least 20 healthy
donors and stored until use at 270uC. Serum was inactivated by
heating at 56uC for 20 min. Isolation of lipid free serum was
performed as described [1]. Briefly, EDTA-plasma or clarified
lepuridin-plasma was applied on a gradient of potassium bromide
and ultracentrifuged at 166.000 g for 22 h at 4uC. The lipid free
serum fraction was isolated from the gradient with a density
heavier than 1.25. The lipid fractions with a density between 1.063
and 1.210 and between 1.019 and 1.063 were used as the fractions
containing HDL and LDL, respectively. Fractions were dialyzed
against PBS, filtered (0.22 mm) and stored at 4uC until use. The
concentration of HDL and LDL is expressed as the equivalent
concentration of cholesterol in micrograms per milliliter. The
purified lipoprotein and lipid free serum fractions obtained from
the clarified lepirudin plasma were subject to a HPLC analysis.
The lipid free serum fraction from the EDTA-plasma was
subjected to a hexane extraction to remove the remaining lipid
particles from the serum. The serum fraction and hexane 3:1 (v/v)
were incubated for 30 min while vigorously shaking. The aqueous
partition was dialyzed against PBS. The protein content was
measured with a standard BCA kit and concentrated with an
Amicon 10 kDa cut-off filter (Millipore) to adjust the protein
content to the level present in normal human serum.
Calcium mobilization in human neutrophils and HL-60
cells
Calcium mobilization with isolated human neutrophils and HL-
60/FPR2 cells was performed as previously described [13]. For
this purpose, cells (5610
6 cells/ml) were loaded with 2 mM Fluo-3-
AM for 20 min at room temperature, protected from light with
gentle agitation. The cells were washed, resuspended in RPMI-
HSA (without FCS) to 5610
6 cells/ml. Stimuli were prepared by
incubating 25 ml of 10 times concentrated agonist with 25 ml1 0
times concentrated heat inactivated serum, HDL, LDL or buffer
for 30 min at room temperature. Before stimulation, cells were
diluted to 1610
6 cells/ml in a volume of 200 ml. The basal
fluorescence level for Fluo-3 was monitored at 530 nm for 8 sec
after which 50 ml of pre-incubated stimulus was added. The
sample tube was rapidly placed back to the sample holder and the
fluorescence measurement continued up to 52 sec. Cells were
gated based on scatter parameters to exclude cell debris and the
mean fluorescence value at basal level was subtracted from the
value at peak level (at 30 sec). The different fluorescent values
were expressed as percentage of the maximal response for each
individual stimulus. Alternatively, various concentrations of
culture supernatants or synthetic PSM, pre-incubated with 1%
or 0,1% heat inactivated serum for 30 min, were added to Fluo-3-
labeled HL-60/FPR2 cells followed by flow cytometry. For
inhibition kinetics, 10 times concentrated PSM were incubated
with 0.1% serum and at different time-points of incubation
samples were added as stimuli for HL-60/FPR2 cells in the flow
cytometer.
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Lysis of human neutrophils by filter-sterilized S. aureus culture
supernatants or synthetic PSM was measured as described [36,37].
Clarified culture supernatants were pre-incubated with different
concentrations of human serum for 10 min at room temperature.
Pre-treated supernatants were transferred to a 96-wells ELISA
plate (Nunc) containing 3610
6 neutrophils in a total volume of
100 ml RPMI-HSA and were incubated for 15 min at 37uC.
Neutrophil lysis was determined by release of lactate dehydroge-
nase (LDH) using the CytoTox 96 Non-Radioactive Cytotoxicity
kit (Promega). Alternatively, synthetic PSM were incubated for
10 min at room temperature with serum, serum gel filtration
fractions or lipoproteins and subsequently tested in the neutrophil
lysis assay.
Gel filtration of PSM-FITC with serum
To study the PSM interaction with serum components,
synthetic PSMa3 was labeled with fluorescein isothiocyanate
(FITC), by incubating 1 mg/ml PSMa3 with 100 mg/ml FITC in
0.1 M sodium carbonate buffer (pH 9.6) for 1 hour at 37uC.
FITC-labeled PSMa3 (PSMa3-FITC) was separated from un-
bound FITC using a HiTrap desalting column (Amersham
Biosciences). To determine the retention volume of PSMa3o r
PSMa3-FITC alone, 100 mg/ml was loaded onto a Superdex 200
10/300GL (GE Healthcare) equilibrated with PBS. The interac-
tion with serum components was studied by incubating 100 mg/ml
PSMa3-FITC with 10% human serum, 2 mg/ml HDL or 1 mg/
ml LDL. In some experiments, 500 ml fractions were collected
after column passage and fluorescence was quantified with a
platereader fluorometer (Flexstation, Molecular Devices). Protein
content was measured at OD280 nm and the FITC-extinction was
measured at OD492 nm on an AKTA explorer (Amersham).
Serum and lipoproteins had minimal auto extinction at
OD492 nm allowing measurement of the association of PSMa3-
FITC with serum components at OD492 nm. The column was
calibrated using the HMW Calibration kit (GE Healthcare)
containing Thyroglobulin (669 kDa), Ferritin (440 kDa), Aldolase
(158 kDa), Conalbumin (75 kDa) and Ovalbumin (43 kDa). In
some experiments, 100% heat inactivated serum was separated by
gel filtration and subsequently 0.5 ml fractions were collected for
further analysis. In other experiments, 100 mg/ml PSMa3-FITC
in PBS containing 0.1% sodium-desoxycholate (PBS-DOC) was
applied to the gel filtration column equilibrated with PBS-DOC.
Serum pull-down assays and proteomics
PSMa1 and PSMa3 were immobilized on CNBr-Sepharose
(Amersham) fast flow according to the manufacturer’s suggestions.
The coupling density was 2.5 mg/ml of resin for both PSM.
Following quenching of excess reactive groups with 1 M
ethanolamine (pH 8.0) for 2 h at room temperature, the affinity
resins were washed and stored as 50% slurries in PBS. To test for
binding to serum proteins, heat inactivated human serum was
diluted 1:20 in PBS and mixed individually with 20 ml of each
affinity resin in a total volume of 0.5 ml. After a 30 min incubation
at room temperature under vigorous agitation, the resins were
pelleted by centrifugation at 3500 g for 2 min, and washed five
times with 1 ml of PBS or PBS containing 0.1% Tween20 (PBST).
After the last wash, each resin was resuspended in 20 mlo f2 6
Laemmli sample buffer, mixed briefly, and heated at 95uC for
5 min. Following sample preparation, the proteins contained in
each sample were separated by 12.5% SDS-PAGE and visualized
by instant blue staining. For protein identification, the bands of
interest were excised from the gel and subjected to in-gel
proteolysis by trypsin as described by [38]. The resulting tryptic
fragments were extracted, separated by capillary liquid chroma-
tography (LC), and characterized by tandem mass spectrometry
(MS/MS). Proteins were identified by comparing the observed
fragmentation ion patterns against a data base of human proteins
using the MASCOT software package.
HPLC analysis
Analytical HPLC was performed using an automatic HPLC
system (Shimadzu) with an analytical reversed-phase column, an
UV detector operating at 214 nm with a flow rate of 0.75 mL/
min. A Phenomenex Gemini C18 (110 A ˚,5mm, 25064.6 mm)
column was used. TFA buffers (buffer A: H2O:MeOH, 95:5, v:v;
buffer B: MeOH:H2O, 95:5, v:v, both containing 0.1% TFA).
Elution was effected with either a linear gradient from 100% A to
100% B over 60 min or a linear gradient from 40%A to 100%B
over 45 min. The molecular mass in the respective peak was
determined using electrospray mass spectrometry (ESI-MS), which
was performed on a Thermo Finnigan LCQ DECA XP MAX ion
trap mass spectrometer and respective PSM were identified and
matched in both retention time and mass synthetic PSM. d-toxin
and PSMa2 were not separated in both systems.
Generation of PSMa promoter-GFP construct
The PSMa promoter-GFP construct was made similar to the
method described previously [39]. Shortly, 270 bp upstream of the
PMSa1 start codon (excluding the SD sequence) was amplified by
PCR using Phusion polymerase (Finnzymes), using the following
primers 59-AGAATTCGCATGCCTAACGTGTTATTCGTT-
TTAAACTTAT-39) and 59-GGATCCTCTAGATTTGCTTA-
TGAGTTAACTTCATTGTA-39 (Life Technologies) and chro-
mosomal DNA from strain Newman as template. Purified PCR
products were digested with XbaI and EcoRI (New England
Biolabs) and ligated in the likewise digested shuttle vector pSK236-
GFP-uvr [39]. The ligation mixture was introduced in E. coli
Top10F9 using the CaCl2 method [40]. Colonies were checked for
GFP expression using an ImageQuant LAS4000 (GE Healthcare
Life Sciences), and positive clones were checked by restriction
analysis and sequencing of the insert. Correct plasmids were
introduced into S. aureus strain RN4220 by electroporation as
described by [41], re-isolated, and introduced by electroporation
in S. aureus MW2 and the MW2 Agr knockout.
GFP reporter assays
To measure the GFP expression of the S. aureus strains MW2 the
MW2 agr KO in culture, the strains containing the PSMa
promoter-GFP construct were grown in MHB with 10 mg/ml
chloramphenicol. Overnight cultures were diluted 1:10000 and
grown to an OD660 of 0.1. The cultures were transferred to a clear
96 well flat bottom polystyrene tissue culture plates (Greiner) using
150 ml culture/well. The plate was grown in a Fluostar Omega
plate reader (BMG labtech) at 37uC with constant double orbital
shaking (400 rpm) in between measurements. Both the absorbance
at 660 nm and GFP fluorescence (excitation 485 nm/emission
520 nm) were measured every 10 minutes for each well. The
signal from 4 identical wells was averaged and corrected for blank
wells containing only medium.
To detect GFP expression in neutrophils after phagocytosis of S.
aureus, an overnight culture of S. aureus MW2, containing the
PSMa promoter-GFP construct, was diluted 100006in MHB and
allowed to grow till OD660 0.08. Then, the bacteria were collected
by centrifugation and washed once in PBS. Bacteria were
opsonized in 10% human serum in RPMI for 59 at 37uC, washed
once in PBS and resuspended in RPMI/HSA to an OD660 of 0.01,
which corresponds to 5610
6 bacteria/ml. A three-channel flow
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size 1,5 (VWR International BV, The Netherlands) mounted at
the underside) with channel dimensions of 164640 mm was
assembled and sterilized as described [42]. To promote adherence
of neutrophils, the channels were coated with 25% human serum
in RPMI by flowing in the serum, stopping the flow, clamping off
the channels on both sides, and incubating overnight at 4uC.
Before introduction of neutrophils, the channels were flushed with
RPMI to remove unbound serum. Freshly isolated neutrophils
were diluted to 5610
5/ml and 200 ml was injected into each
channel of the serum-coated flow cell. Neutrophils were allowed to
adhere for 30 minutes at RT, after which the opsonized bacteria
were injected in the channel at a ratio of 10 bacteria: 1 neutrophil.
The channel was clamped on both sides, the tubes were cut and
the flow cell was transferred to the microscope stage. Neutrophils
and bacteria were imaged using a Leica TSC SP5 inverted
microscope equipped with a HCX PL APO 406/0.85 objective
(Leica Microsystems, The Netherlands). The microscope was
encased in a dark environment chamber that was stably kept at
37uC. 15 minutes after phagocytosis images were acquired using
the camera every 5 minutes in both the bright field and the GFP
channel (I3 filter cube) for 3 hours to follow GFP production. In
post processing the bright field image was not altered and the
green channel was adjusted in LAS AF (Leica) to contrast +10,
brightness 210 and gamma 1.3 to reduce the green background
before merging of both channels.
Supporting Information
Figure S1 Inhibition of PSM-related functions in culture
supernatants by human serum. (A) Dose-dependent calcium
mobilization of HL-60/FPR2 cells by the culture supernatants of
S. aureus strains USA300 Newman, MW2, COL and N315 with or
without preincubation in 1% heat inactivated human serum. (B)
Dose-dependent neutrophil lysis by S. aureus culture supernatants
with or without 5% human serum. Neutrophil lysis was measured
via LDH release. Data represent means 6 SEM of three
independent experiments.
(TIF)
Figure S2 Inhibition of PSM-mediated PBMC lysis and
no inhibition of PVL-mediated neutrophil lysis by
human serum. (A) Dose-dependent PBMC lysis by synthetic
PSMa3 preincubated with or without 1% or 10% human serum.
(B) Dose-dependent neutrophil lysis by recombinant PVL protein
(LukS and/or LukF) with and without 5% serum. Leukocyte lysis
was measured via LDH release. Data represent means 6 SEM of
three independent experiments.
(TIF)
Figure S3 Calcium mobilization of human neutrophils
induced by PSMa3 or PSMa3-FITC. Neutrophils were
stimulated with a dose response of 1.3610
29 Mt o1 0
26 M
PSMa3 or PSMa3-FITC. Data represent means 6 SEM of three
independent experiments.
(TIF)
Figure S4 Monomerization of PSM by serum lipopro-
teins. Gel filtration association assay. Comparison of extinction
(OD280 nm) profiles of 100 mg/ml PSMa3-FITC pre-incubated
(A) 10% human serum, (B) 1 mg/ml HDL, (C) 1 mg/ml LDL or
(D) 1 mg/ml VLDL for 30 min, before separation on a gel
filtration column. Representative figures of two independent
experiments.
(TIF)
Figure S5 No inhibition of neutrophil activation or lysis
by recombinant apolipoproteins. (A) Dose-dependent neu-
trophil activation by synthetic PSMa3 preincubated with ApoA1
(50 mg/ml) or ApoB1 (50 mg/ml) or buffer, calcium mobilization
was measured by flow cytometry. (B) Dose-dependent neutrophil
lysis synthetic PSMa3 preincubated with ApoA1 50 mg/ml or
ApoB1 50 mg/ml or buffer. Neutrophil lysis was measured via
LDH release. Data represent means 6 SEM of three independent
experiments.
(TIF)
Video S1 Time lapse images showing neutrophils which
have phagocytozed S. aureus MW2 containing the PSMa
promoter-GFP construct, PSMa expression (green) was
monitored over time. The video starts 15 min after phagocy-
tosis and the images were taken by every 5 minutes. Note, the
upper right corner shows a growing S. aureus reporter micro-colony
which shows no PSM-a expression.
(MOV)
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